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Abstract
·AIM: To assess the association between age -related
macular degeneration (AMD) and three single nucleotide
polymorphisms (SNPS) related to the vascular endothelial
growth factor (VEGF) gene.
·METHODS: The patients who were diagnosed with AMD
were included in this prospective study. Three SNPs
(rs1413711, rs2146323, and rs3025033) of the VEGF gene
were genotyped by real-time polymerase chain reaction
in the genomic DNA isolated from peripheral blood
samples of the 82 patients and 80 controls.
·RESULTS: The genotype frequencies of rs1413711 and
rs2146323 were not significantly different between the
study group and the control group ( =0.072 and =0.058).
However, there was a significant difference in the
genotype frequencies of these SNPs between the wet
type AMD and dry type AMD ( =0.005 and =0.010,
respectively). One of the SNPs (rs1413711) was also
found to be associated with the severity of AMD ( =0.001)
with significant genotype distribution between early,
intermediate, and advanced stages of the disease. The
ancestral alleles were protective for both SNPs while the
polymorphic alleles increased the risk for dry AMD.
·CONCLUSION: VEGF SNPs rs1413711 and rs2146323
polymorphisms are significantly associated with AMD
subtypes in our population.
·KEYWORDS: age-related macular degeneration; vascular
endothelial growth factor; single nucleotide polymorphism
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INTRODUCTION
A ge-related macular degeneration (AMD) is amultifactorial disease that represents the most common
cause of irreversible visual impairment in the elderly
population [1]. Patients with this disease eventually develop
either neovascularization (wet type) or geographic atrophy.
Wet type AMD is characterized by choroidal
neovascularization (CNV), which causes exudative and
hemorrhagic changes in the retina and eventually significant
visual loss in a majority of the cases[2-4].
Risk factors of AMD are heterogeneous, including mainly
increasing age and different genetic predispositions, together
with several environmental/epigenetic factors [1]. There is
extensive support for a strong genetic component in AMD
pathogenesis[2].
VEGF is an important factor during angiogenesis, and
elevated VEGF concentration in CNV suggested that VEGF
is also important in CNV formation. Several studies found
increased levels of VEGF in the vitreous samples of patients
with wet AMD. The VEGF protein level was associated with
single nucleotide polymorphisms (SNPs) in the promoter and
untranslated region (UTRs) of the gene. So, a number of
studies have been focused on the relation between the SNPs
of the gene and AMD. But there is no consensus between the
results, and it is thought that many factors such as ethnical
differences, environmental factors, etc., might be responsible
for this difference [5]. Recently, it has been reported that
genetic variations might be associated with treatment
response in wet type AMD patients [6-10]. Therefore, a better
understanding of the relation between genetic factors and
AMD may affect the therapeutic decisions in patients with
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AMD in the future.
Here, we report the association of VEGF gene rs1413711,
rs2146323, and rs3025033 polymorphisms in a Turkish
population with AMD, and to our knowledge, this is the first
report from our country.
SUBJECTS AND METHODS
Patients and Controls The patients who were diagnosed
with AMD at the Department of Ophthalmology, Pamukkale
University, were included in this prospective study. The
control group consisted of the patients without visual
impairment, drusen, or retinal pigment epithelium (RPE)
changes under dilated fundus examination. A total of 162
subjects were included in the study. Of the 162 subjects, 82
(50.6%) had AMD and 80 (49.4%) comprised the control
group.
The patients who were younger than 55y and had diabetes
mellitus, glaucoma, high myopia (>6 D), retinal pathology, or
any disease that can lead to CNV (angioid streak,
inflammation, trauma .) were excluded from the study.
Institutional review board approval was obtained prior to the
beginning of the study, and all participants provided written
informed consent. The methods used in this study conformed
to the tenets of the Declaration of Helsinki (2008) of the
World Medical Association.
All participants underwent a detailed ophthalmologic
examination, including measurement of best corrected visual
acuity, intraocular pressure, anterior segment examination
with slit-lamp, and posterior segment examination with
slit-lamp and fundoscopy lens. A colour fundus picture was
obtained for all participants and a fluorescein angiography for
the study group. The AMD stage assigned was based on the
most severe eye at the time of recruitment. The severity of
AMD was classified as early, intermediate, and advanced as
previously defined in age related eye disease study (AREDS)
report No:6 (early for grade 1 and 2, intermediate for grade 3,
and advanced for grade 4) [11]. The size of drusen was
classified as small (<63 滋m), medium (63-125 滋m), and
large (>125 滋m), whereas the type of drusen was classified
as soft, hard, and confluent drusen.
Genotyping Peripheral blood samples were collected from
the subjects. Genomic DNA was extracted from all samples
of 200 滋L whole blood using a commercial kit (High Pure
PCR Template Preparation Kit, Roche Diagnostics,
Germany). Three SNPs, including rs1413711, rs2146323, and
rs3025033 in the VEGF gene, were studied. Primers and
probes that amplify 158 bp, 200 bp, and 124 bp target
sequences (for rs1413711, rs2146323, and rs3025033,
respectively) are shown in Table 1. Real-time PCR analyses
were performed on the LightCycler 480 Real-Time PCR
System (Roche Diagnostics). The cycling conditions for all
SNPs were: 10min at 95℃ for activation, followed by
35 cycles of 95℃ for 10s, 56℃ (for rs1413711 and
rs2146323) and 54℃ (for rs3025033) for 10s, and 72℃ for
10s. For the amplicon identification, the following conditions
were used: 30s at 95℃ , 45s at 40℃ , and 0s at 85℃ for one
cycle.
Statistical Analysis Statistical analysis was carried out by
SPSS (version 11; SPSS Inc., Chicago, IL) software. The
Chi-square analysis was used to test the significance of the
differences of observed alleles and genotypes between
groups. A logistic regression model was used to calculate the
odds ratios and 95% confidence intervals (CI).
RESULTS
Patients' Characteristics A total of 162 subjects were
included in the study. Of 162 subjects, 82 (50.6%) had AMD
and 80 (49.4%) comprised the control group. Table 2 shows
the demographics of the study and the control groups.
Because of the significant difference in age between the study
and the control groups, the statistical analysis was adjusted by
age. The type and the severity of AMD in the study group are
shown in Table 3.
Table 1 Primer and probe sequences for VEGF genotyping  
SNP Sequence (5’→3’) 
rs1413711   
Primer sense 5’-TGACAATATTCTCCCGGGACC-3’ 
Primer antisense 5’-AGTGTGACCTTCAGAGGCCC-3’ 
Probe-1 5’-CTTCCAAGGCCAGGGGGCA-3’-FLa 
Probe-2 b5’L640-AGGAGGGGCGGTTCTAGGCAGGCA-3’ 
rs2146323   
Primer sense 5’-AAGCTTAGGGAAGTGCTTCAA-3’ 
Primer antisense 5’-CTGCGCTGATAGACATCCAT-3’ 
Probe-1 5’-TGTAATGCCACTCTTTGGAGCTT-3’-FLa 
Probe-2 b 5’L640-GAATCAGGCAAGTCCTTCC-3’ 
rs3025033   
Primer sense 5’-AAGACTTTGTGGGGATTTCCTA-3’ 
Primer antisense 5’-TTGGTTTCACATAGGGCCAA-3’ 
Probe-1 5’-AGGGAAGTCCTTGGAGTGTCTCCCC-3’-FLa 
Probe-2 b 5’L640-CCCCAGCAATGTTCTTGTGGC-3’ 
aFL: Fluorescein; b640: LightCycler-Red 640. 
 
Table 3 The type and the severity of AMD in the study group 
Parameters n (%) 
AMD type   
  Wet 43 (52.4) 
  Dry 39 (47.6) 
Severity of AMD  
  Early 11 (13.4) 
  Intermediate 21 (25.6) 
  Advanced 50 (62) 
Size of Drusen  
  Small (<63µm) 44 (53.7) 
  Medium (63-125µm) 27 (32.9) 
  Large (>125µm) 11 (13.4) 
Type of Drusen  
  Hard  45 (54.9) 
  Soft 33 (40.2) 
  Confluent 4 (4.9) 
 
Table 2 Demographics of the study and the control groups  sx ±  
Parameters AMD Control P 
Age (a) 71.7± 5.3 62.8± 5.2 <0.001 
Gender n(%)   0.534 
  F 37 (45.1) 40 (50)  
  M 45 (54.9) 40 (50)  
 
Gene polymorphisms in age related macular degeneration
774
陨灶贼 允 韵责澡贼澡葬造皂燥造熏 灾燥造援 7熏 晕燥援 5熏 Oct.18, 圆园14 www. IJO. cn
栽藻造押8629原愿圆圆源缘员苑圆 8629-82210956 耘皂葬蚤造押ijopress岳员远猿援糟燥皂
Vascular Endothelial Growth Factor Genotype
Frequencies and Association of Patient Characteristics
with the Genotype Genotype distribution of the all SNPs in
the VEGF gene in patients with AMD and healthy controls
are listed in Tables 4 and 5. The positions of the three SNPs
analyzed in this study are shown in Figure 1. We could not
find a significant difference in rs1413711 genotypes between
the patients and controls ( =0.72), but there was a
significant difference between wet and dry AMD with regard
to rs1413711 genotypes ( =0.005). We also found that the
presence of an A allele was significantly associated with the
disease (OR=2.25; 95% CI 1.15-4.43).
For rs2146323, there was no significant difference between
patients and controls ( =0.058). We have also observed that
the frequency of the genotypes is significantly higher in
patients with dry AMD compared to patients with wet AMD
( =0.010). The presence of at least one A allele was
significantly associated with the disease (OR= 2.02; 95% CI
0.99-4.16). In the case of dry AMD, this association was
more prominent (OR=4.29; 95% CI 1.38-13.37) compared to
wet AMD (OR=1.27; 95% CI 0.56-2.86).
The AA genotype at rs3025033 was the most prevalent
genotype in both patients and controls (97.6% and 98.8%,
respectively). There was no difference in genotype
distribution between dry and wet AMD groups ( =0.616).
We found that the presence of ancestral allele (G) in
rs1413711 was protective for all AMD patients (OR 0.47
95% CI 0.24-0.91); however, the risk for AMD was
increased in patients with AA genotype (OR 2.00 95% CI
1.04-3.84), and AA genotype comprised a highly increased
risk for dry AMD (OR 4.28 95% CI 1.61-11.35). The
association between the disease and the presence of at least
one A allele at the rs1413711 was particularly observed in
the case of dry AMD, where the risk was almost 7 times
higher than the control group (OR 6.47, 95% CI 2.10-19.93).
As for rs2146323, the ancestral C allele was highly protective
(OR 0.45 95% CI 0.28-0.71), whereas homozygous presence
of the A allele was found to pose a highly increased risk for
Table 4 Genotype and allele frequencies of VEGF gene polymorphisms in AMD patients in comparison to controls 
SNP Genotype/allele Patients n (%) Controls n (%) OR (95% CI) 
GG 21 (25.6) 34 (42.5) 0.47 (0.24-0.91)a 
GA 2 (2.4) 1 (1.3) 1.98 (0.18-22.22) 
AA 59 (72.0) 45 (56.2) 2.00 (1.04-3.84) a 
GG vs (GA+AA)   2.25 (1.15-4.43) a 
G 44 (26.8) 69 (43.1) 0.48 (0.30-0.77) a 
rs1413711 
A 120 (73.2) 91 (56.9) 2.07 (1.30-3.30) a 
CC 16 (19.5) 29 (36.3) 0.43 (0.21-0.87) a 
CA 17 (20.7) 20 (25.0) 0.79 (0.38-1.64) 
AA 49 (59.8) 31 (38.7) 2.35 (1.25-4.41) a 
CC vs (CA+AA)   2.02 (0.99-4.16) a 
C 49 (29.9) 78 (48.8) 0.45 (0.28-0.71) a 
rs2146323 
A 115 (70.1) 82 (51.2) 2.23 (1.42-3.52) a 
AA 80 (97.6) 79 (98.8)  
AG 1 (1.2) 1 (1.2)  
GG 1 (1.2) 0 (0)  
A 161 (98.2) 159 (99.4)  
rs3025033 
G 3 (1.8) 1 (0.6)  
VEGF: Vascular Endothelial Growth Factor; OR: Odds Ratio; CI: Confidence Interval; a The significant P values. 
Table 5 The genotype and allele frequencies of VEGF SNPs according 
to the type of AMD 
Parameters Patients  n (%) 
Controls  
n (%) OR (95% CI) 
rs1413711  
Wet AMD    
GG 17 (39.5) 34 (42.5) 0.89 (0.42-1.88) 
  GA 0 (0) 1 (1.3) - 
  AA 26 (60.5) 45 (56.2) 1.19 (0.56-2.50) 
  GG vs (GA+AA)   1.13 (0.53-2.41) 
  G 34 (39.5) 69 (43.1) 0.86 (0.51-1.47) 
  A 52 (60.5) 91 (56.9) 1.16 (0.68-1.98) 
Dry AMD    
  GG 4 (10.3) 34 (42.5) 0.16 (0.05-0.48)a 
  GA 2 (5.1) 1 (1.3) 4.27 (0.38-48.60) 
  AA 33 (84.6) 45 (56.2) 4.28 (1.61-11.35)a 
  GG vs (GA+AA)   6.47 (2.10-19.93)a 
  G 10 (12.8) 69 (43.1) 0.19 (0.09-0.40)a 
  A 68 (87.2) 91 (56.9) 5.16 (2.48-10.74)a 
rs2146323    
Wet AMD    
  CC 12 (27.9) 29 (36.3) 0.68 (0.30-1.53) 
  CA 12 (27.9) 20 (25.0) 1.16 (0.50-2.68) 
  AA 19 (44.2) 31 (38.7) 1.25 (0.59-2.65) 
  CC vs (CA+AA)   1.27 (0.56-2.86) 
  C 36 (41.9) 78 (48.8) 0.76 (0.45-1.28) 
  A 50 (58.1) 82 (51.2) 1.32 (0.78-2.24) 
Dry AMD    
  CC 4 (10.3) 29 (36.3) 0.20 (0.07-0.62)a 
  CA 5 (12.8) 20 (25.0) 0.44 (0.15-1.28) 
  AA 30 (76.9) 31 (38.7) 5.27 (2.21-12.58)a 
  CC vs (CA+AA)   4.29 (1.38-13.37)a 
  C 13 (16.7) 78 (48.8) 0.21 (0.11-0.41)a 
  A 65 (83.3) 82 (51.2) 4.76 (2.43-9.31)a 
VEGF: Vascular Endothelial Growth Factor; OR: Odds Ratio; CI: 
Confidence Interval; aThe significant P values. 
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dry AMD (OR 5.27 95% CI 2.21-12.28). The presence of at
least one A allele was associated with dry AMD (OR 4.29,
95% CI 1.38-13.37).
In the analysis of clinical variables and VEGF SNPs, there
was no difference between patients and controls with regard
to sex and type of drusen. However, the presence of AA
genotype at rs1413711 was significantly related to the stage
of disease ( =0.001) (Table 6), and the presence of one A
allele was significantly associated with the size of drusen
( =0.042).
DISCUSSION
In this study, we analyzed three intronic SNPs along the
VEGF gene and found that the ancestral alleles of both
rs1413711 and rs2146323 were protective against AMD,
whereas the presence of the polymorphic alleles increased the
risk for the disease, particularly in the case of dry type, in a
Turkish population. Additionally, rs1413711 was
significantly associated with the stage of AMD.
Since introduction as a risk factor for AMD, the genetic
variations have been widely studied in different populations.
Studies from different populations have revealed the
association of VEGF polymorphism and AMD types, and
also the impact of VEGF polymorphisms to the outcomes of
anti-VEGF treatment. However, there is inconsistency among
the findings of those studies.
Association between rs1413711 and AMD was previously
studied, but the results of these studies are inconsistent. In a
study conducted in a Caucasian population from Northern
Europe, Churchill [12] genotyped 45 patients with AMD
and 94 healthy controls and reported that the GG genotype in
rs1413711 SNP was significantly associated with AMD,
whereas the presence of A allele was potentially protective.
In a Taiwan Chinese cohort of 190 late AMD patients and
180 controls, Lin [13] genotyped five SNPs and did not
found an association between rs1413711 and AMD. In
another study with 159 neovascular AMD and 140 age- and
sex-matched controls from China, Qu [14] found no
association between the VEGF SNPs, including rs1413711
and AMD. Almeida [15] genotyped the SNP in 160
patients with AMD and 140 healthy controls in a Brazilian
cohort, and they found an association between the mutant
allele and the disease. In a recent meta-analysis study, Lu
[16] reported that there was a significant relation between
rs1413711 polymorphism and AMD risk among Europeans.
We found that A is the risk allele for rs1413711 in our study
group while G had a protective effect. G is the ancestral
allele for this SNP in the dbSNP database (http://www.ncbi.
nlm.nih.gov/snp). This SNP is highly variable in our study
group with an allele frequency of A, 73.2% in cases and
56.9% in controls.
Association between rs1413711 and response to anti-VEGF
treatment in AMD is also studied widely. In two recent
papers Yuan [17] and Dos Reis Veloso [18] studied
this association. Yuan [17] found TT and CT genotypes
were associated with improved visual acuity in anti-VEGF
treatment, while the others [18] found no association between
the VEGF genotypes and the treatment outcome.
Haines [19] analyzed eight genes including VEGF in two
independent datasets consisting of a family-based association
dataset (162 families) and a case control dataset (399 cases
and 159 controls) for genetic linkage and association with
AMD. They studied five SNPs in the VEGF gene including
rs2146323 and found no significant association of this SNP
with AMD. Also, Churchill [12] tested rs2146323 in their
study but could not find any association with AMD. Fang
[20] tested nine SNPs including rs1413711, and
rs2146323 in a cohort of 515 Caucasian wet AMD patients
for association with AMD and found that none of the
investigated SNPs were associated with the disease. In
contrast to these studies, we found that ancestral C allele of
Figure 1 The approximate positions of the three SNPs of VEGF gene analyzed in our study. Black, gray, and white boxes indicate
the exons, untranslated regions (UTRs) and the introns, respectively.
Table 6 Genotype distribution of VEGF SNPs by AMD stage 
Stages of AMD 
Genotype Early n (%) Intermediate 
n (%) 
Advanced 
n (%) P 
rs1413711     
GG 1 (9.1) 2 (9.5) 18 (36.0) 
GA 2 (18.2) 0 0 
AA 8 (72.7) 19 (90.5) 32 (64.0) 
0.001 
Rs2146323     
CC 0 4 (19.0) 12 (24.0) 
CA 3 (27.3) 1 (4.8) 13 (26.0) 
AA 8 (72.7) 16 (76.2) 25 (50.0) 
0.085 
rs3025033     
AA 11 (100.0) 21 (100.0) 48 (96.0) 
AG 0 0 1 (2.0) 
GG 0 0 1 (2.0) 
0.859 
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rs2146323 was highly protective against dry AMD, and also
homozygosity of the A allele was associated with the disease.
Immonen [7] analyzed the association of rs2146323 and
rs3025033 with the risk of AMD, CNV size and
configuration, and the anatomic response to photodynamic
therapy in 162 patients with exudative AMD and 85
age-matched controls. They found no association between the
SNPs and the presence of the disease, lesion size and
configuration. The genotype frequencies of the rs2146323
were significantly different between the photodynamic
therapy (PDT) responders and non-responders, but rs3025033
genotype distribution was even between the two groups. Our
findings for rs3025033 was not suitable for a statistical
analysis because homozygosity of the ancestral A allele was
almost always present in cases and controls except for 2
individuals (1 wet AMD and 1 control) with AG and 1
individual (wet AMD) with GG genotype.
In conclusion, we found that the polymorphisms of VEGF are
associated with the dry AMD in our population. Since the
genetic variations were shown to be associated with
treatment response in AMD patients receiving anti-VEGF
treatment, further data from future studies would determine
whether VEGF polymorphisms might play a role in treatment
decisions in a perspective of personalized medicine.
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